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Abstract: Cardiovascular disease represents the leading cause of morbidity and mortality in 
Western countries, and hypertension-related cardiovascular events affect about 37 million people 
per year, worldwide. In this perspective, hypertensive patients are at increased risk to experience 
cardiovascular events during life-long period, and treatment of high blood pressure represents 
one of the most effective strategies to reduce global cardiovascular risk. However, due to its 
multifactorial pathophysiology and its frequent association with other relevant risk factors and 
clinical conditions, treatment of hypertension requires an integrated approach, including life-
style measures, antihypertensive drugs and other therapies. Yet, worldwide general practitioners 
continue to focus their attention on the management of a single risk factor, eg, blood pressure, 
rather than to global cardiovascular risk proﬁ  le. In this view, modern strategies of cardiovascular 
prevention in hypertensive patients should move from a single risk factor based approach toward 
a more comprehensive risk evaluation in the individual patient. In other words, it is important 
to deﬁ  ne the global cardiovascular risk to manage hypertensive patients at high-risk, rather than 
to focus on the high level of a single risk factor, for reducing cardiovascular morbidity and 
mortality in the general population, as well as in hypertensive population. 
Keywords: hypertension, hypercholesterolemia, cardiovascular prevention, global 
cardiovascular risk 
Introduction
Hypertension represents today a major public concern. In fact, it affects more than 
20% of the adult population in Western countries and about a billion people worldwide 
(Collins et al 1990; MacMahon et al 1990). The presence of high blood pressure levels 
doubles the risk of ischemic heart disease and increases by four-fold incidence of stroke 
(Van den Hoogen et al 2000; Lewington et al 2002). On the other hand, treatment of 
hypertension reduces by approximately 40% stroke incidence and by about 14% coro-
nary events (BPLTTC 2000). In spite of these evident beneﬁ  ts, only 20% of hypertensive 
patients receive an adequate treatment to keep blood pressure within the recommended 
threshold of normality (HDFPCG 1979; Wolf-Maier et al 2003). Together with the other 
modiﬁ  able cardiovascular risk factor, such as hyperglicemia, hypercholesterolemia, 
smoking and obesity, hypertension heavily contributes to the global cardiovascular 
burden of morbidity and mortality, as well as to increase individual absolute cardiovas-
cular risk (Kannel 2000). In this view, modern strategies of cardiovascular prevention 
should consider a more comprehensive evaluation of risk factor proﬁ  le in the individual 
patient (ESH/ESC 2003; WHO/ISH 2003; ADA 2003). 
The clustering of cardiovascular risk factors in hypertensive patients is indeed an 
extremely frequent observation in both epidemiological studies and clinical practice, 
and less than 20% of hypertensive patients have no associated risk factors, whereas 
the remaining 80% have one or more associated risk factors (Kannel 2000). As ad-
dressed in the most recent European Guidelines on hypertension (ESH/ESC 2003), the Vascular Health and Risk Management 2007:3(3) 314
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Figure 1 Absolute risk of cardiovascular disease over 5 years in patients by systolic blood pressure at speciﬁ  ed levels of other risk factors. Copyright © 1991. Derived from 
Anderson KM, Odell PM, Wilson PW, et al 1991. Cardiovascular disease risk proﬁ  les. Am Heart J, 121(1 Pt 2):293–8. 
concomitant presence of risk factors in hypertensive patients 
translates in progressively higher absolute cardiovascular risk, 
as clearly demonstrated about 15 years ago in the Framingham 
Heart Study (Andersson et al 1998). Depending upon the 
co-existence of none, one, two or more risk factors or dia-
betes, the level of added risk rises from low to moderate or 
high risk, as represented in Figure 1. 
In this view, as the beneﬁ  ts of reducing blood pressure are 
proportional to the levels of risk, in high-risk hypertensive pa-
tients a tighter control of blood pressure levels is recommended, 
and will result in a progressively greater beneﬁ  t. In speciﬁ  c con-
ditions, such as in the presence of concomitant diabetes, lower 
blood pressure targets are recommended to ensure a larger impact 
on outcomes, as it has been demonstrated in the United Kingdom 
Prospective Diabetes Study (UKPDS) (UKPDS 1998). 
Recommendations derived from guidelines (ESH/ESC 
2003) and recent observations from large international tri-
als in hypertension (Yusuf et al 2002; Gaede et al 2003) 
clearly indicate that a prompt and tight control of blood 
pressure may reduce cardiovascular events in high-risk sub-
jects. In this view, patients with hypertension and multiple 
concomitant risk factors, as those included in the Valsartan 
Antihypertensive Long-term Use Evaluation (VALUE) study 
(Julius et al 2004), deserve closer clinical observation and 
more prompt and aggressive therapeutic control of blood 
pressure levels aiming at the achievement of target levels 
of or below. In these patients multiple (two up to four) 
antihypertensive agents are often required to achieve the 
recommended targets. However, the achievement of blood 
pressure targets is difﬁ  cult in such patients, and therefore, in 
order to adequately reduce the level of risk, other therapeutic 
strategies aimed at reducing the inﬂ  uence of concomitant 
risk factors (eg, lipid-lowering agents or aspirin) are helpful 
(HPS 2002; Sever et al 2003; Hansson et al 1998).
On the basis of these evidence, modern strategies of cardio-
vascular prevention in hypertensive patients should move from a 
single risk factor-based approach (eg, focusing on blood pressure) 
toward a more comprehensive evaluation and management of 
risk factor proﬁ  le in the individual patient (Alderman et al 2002; 
Volpe et al 2004). In other words, it is important to adopt a more 
thorough approach aimed at reducing global cardiovascular risk. 
The decision to treat a patient should be based on the level of 
global risk, rather than on the level of a single risk factor. The 
decision about which risk factor, or factors, to treat should be 
also based primarily on the level of risk: the higher the absolute 
risk, the more intensive and extensive the treatment should be 
(Alderman et al 2002; Volpe et al 2004). This approach starts 
and ends with the patient’s global risk rather than on the basis 
of the level of a single risk factor.
Modern view of multiple risk 
management
Over the past two decades, observational studies have 
consistently demonstrated a strong and direct correlation Vascular Health and Risk Management 2007:3(3) 315
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between cardiovascular morbidity and mortality across 
the whole blood pressure spectrum, with no evidence of a 
threshold down to as low as 115/75 mmHg (Collins et al 
1990; MacMahon et al 1990). For instance, the Fram-
ingham Heart Study showed that even slight elevations 
in blood pressure levels to the prehypertensive threshold 
(120–139/80–89 mmHg) is associated with a doubling of 
the incidence of cardiovascular events versus “normal” 
blood pressure levels (<120/80 mmHg) (Vasan et al 2001). 
Consistent evidence supporting a continuous relationship 
between blood pressure and cardiovascular risk can be 
derived from other large epidemiological studies and 
databases (Stamler et al 1986; Yusuf et al 2004). Moreover, 
nonhypertensive individuals with multiple risk factors or a 
history of cardiovascular disease are often at higher absolute 
risk of cardiovascular and renal events than hypertensive 
patients with few or no other additive risk factors (Conroy 
et al 2003). 
As a consequence, guidelines have started to acknowl-
edge the concept that other factors, besides high blood 
pressure levels, may further contribute to determine global 
cardiovascular risk proﬁ  le of an individual patient. Although 
this process is still slow and incomplete, and in some repre-
sentative sets of guidelines, such as in those issued in 2003 
by Joint National Committee (JNC) VII (Chobanian et al 
2003), this is not properly addressed in criteria for diagnosis 
and classiﬁ  cation of essential hypertension. 
Historically, therapeutic intervention thresholds for the 
treatment of cardiovascular risk factors, such as high blood 
pressure, blood cholesterol and glucose levels, have been 
based on different arbitrary threshold of each individual risk 
factor, which have been issued in different sets of guide-
line. Accordingly, physicians frequently persist to focus on 
the treatment of high blood pressure or cholesterol levels, 
rather than on the prevention of high blood pressure or high 
cholesterol-related cardiovascular disease. Because 
risk factors cluster in individuals (Kannel 2000), and there 
is a graded and continuous association between the sum of 
risk factors and overall cardiovascular risk (Stamler et al 
1986; Anderson et al 1991), the contemporary approach to 
treatment should be unequivocally based on the assessment 
of the threshold, at least for cholesterol and blood pressure, 
based on the calculation of estimated coronary (Kannel 2000; 
Conroy et al 2003) or cardiovascular (coronary plus stroke) 
(ESH/ESC 2003, Grundy et al 1998, 1999) risk over a deﬁ  ned 
(usually 5 or 10 years) period.
Evidence derived from large studies demonstrated 
that blood pressure lowering and lipid lowering agents 
may substantially reduce the risk of coronary or major 
cardiovascular events in a broad range of otherwise healthy 
subjects at high-risk proﬁ  le, as well as in hypertensive or 
hypercholesterolemic patients at different thresholds of 
absolute risk (Daholf et al 2002, 2005; Cannon et al 2004; 
Julius et al 2004; LaRosa et al 2005). The absolute beneﬁ  ts 
of these regimens for such patients are substantially greater 
than those achieved in patients with uncomplicated hyper-
tension or hypercholesterolemia. In this regard, even small 
reductions in blood pressure levels, as well as for any other 
traditional risk factor, may generate signiﬁ  cant reduction 
of absolute risk in high-risk patients. As schematically 
shown in Figure 2, the treatment of multiple risk factors 
(eg, blood pressure and blood cholesterol) results in addi-
tive beneﬁ  t, that clearly exceed the advantage of reducing 
aggressively one single risk factor (for instance, normalizing 
blood pressure). 
Although arguments persist about the degree to which 
these effects relate to drug-speciﬁ  c properties, data suggest 
that the size of the risk factor reduction achieved is a more 
important determinant of outcome than the choice of 
drug, especially in high-risk individuals (Anderson et al 
1991). In this type of patients, clinical outcomes trials, 
including the Perindopril pROtection aGainst REcurrent 
Stroke Study (PROGRESS) (PROGRESS 2001), the 
Antihypertensive and Lipid-Lowering treatment to prevent 
Heart Attack Trial (ALLHAT) (ALLHAT 2002), and the 
VALUE studies (Julius et al 2004), support the concept that 
“lower is better” for blood pressure. In addition, evidence 
derived from international, randomized, controlled 
trials, such as the Lipid-Lowering Arm of the Anglo-
Scandinavian Cardiac Outcomes Trial (ASCOT-LLA) (Sever 
et al 2003), the Pravastatin or Atorvastatin Evaluation and 
Infection Therapy–Thrombolysis in Myocardial Infarction 
22 (PROVE IT–TIMI 22) trial (Cannon et al 2004) and 
more recently the Treating to New Targets (TNT) trial 
(LaRosa et al 2005), strongly indicate that in hypertensive 
patients with very high cardiovascular risk an aggressive 
therapeutic approach aimed to lower the serum cholesterol 
concentrations with higher doses of statins rather than 
those commonly used in the clinical practice, signiﬁ  cantly 
reduced the incidence of cardiovascular mortality and 
major cardiovascular events respect to conventional treat-
ment. However, most patients worldwide are neither being 
treated effectively, nor achieving optimal blood pressure 
or cholesterol control (Mancia et al 1997; Libby 2005), 
according with recommendations of the recent guidelines 
(Grundy et al 1999; ESH/ESC 2003). Vascular Health and Risk Management 2007:3(3) 316
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Global cardiovascular risk 
assessment
As previously discussed, the presence of multiple cardiovas-
cular risk factors rather than high level of any single risk factor 
in particular is usually the primary determinant of global risk 
of cardiovascular events in an individual. The absolute risk is 
the likelihood that a person will have a cardiovascular event 
over a given period of time (usually 5 to 10 years) (Grundy 
et al 1999). On the other hand, the relative risk is represented 
by the ratio of the absolute risk of a given patient (or group) 
to that of a low-risk group (Grundy et al 1999). Treatment 
decisions are based on the likelihood an individual will have 
a cardiovascular event over a given period of time (Grundy 
et al 1999). This replaces decision-making based on individual 
risk factor levels. It follows that at a given blood pressure, the 
risk of cardiovascular events can vary widely depending on 
the presence or absence of other nonblood pressure-related 
risk factors. Randomized clinical trials have also shown that 
in persons with a given blood pressure level, the relative risk 
reduction with antihypertensive treatment is similar in those 
with or without other risk factors (Alderman et al 2002). Two 
patients with the same systolic blood pressure may have very 
different global cardiovascular risk depending on the presence 
or absence of other risk factors (Volpe et al 2004). Their rela-
tive treatment beneﬁ  t is the same, but the absolute risk beneﬁ  t 
will be much greater in the higher-risk person.
In whom and when is it appropriate 
to do risk assessment? 
As recommended by the most recent guidelines, risk assess-
ments should be provided at the primary care level by health 
practitioners with appropriate training (Grundy et al 1999; 
Conroy et al 2003). Practitioners should be aware of the 
need to focus on population groups that have a high burden 
of cardiovascular disease. Accordingly, cardiovascular risk 
assessments are recommended:
°  from the age of 45 years for asymptomatic men without 
other known risk factors
°  from the age of 55 years for asymptomatic women 
without other known risk factors.
°  from the age of 35 years for men with other known cardio-
vascular risk factors or at high risk of developing diabetes
High Risk
BP or cholesterol
levels
Global
CV Risk
Figure 2 New paradigms in the management of cardiovascular disease: reduction of single or multiple risk factors generates a beneﬁ  t proportional to the level of Risk. 
Risk increases in relation to clinical characteristics of individual, thus small reductions of each risk factor will produce larger absolute beneﬁ  ts in relation to level of absolute 
risk. Copyright © 2005. Modiﬁ  ed from Volpe M, Ruilope LM, McInnes GT, et al 2005.   Angiotensin-II receptor blockers: beneﬁ  ts beyond blood pressure reduction? J Hum 
Hypertens, 19:331–9.Vascular Health and Risk Management 2007:3(3) 317
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°  from the age of 45 years for women with other known 
cardiovascular risk factors or at high risk of developing 
diabetes.
°  All those with cardiovascular disease should have 
comprehensive risk factor measurements to determine 
the best management approach.
How to perform the risk assessment? 
In the clinical practice, the evaluation of the patient’s 
individual risk can be facilitated by the use of several tools. 
The application of risk charts, for instance, provide either 
advantages (quick and simple means to calculate the global 
cardiovascular risk; projection of the risk of an individual 
over time; comprehensible way to explain the risk factor 
modiﬁ  cation concept to patients; etc), and limitations (lim-
ited number of risk factors that can be included; physicians 
should consider other risk factors and qualiﬁ  ers when esti-
mating individual risk proﬁ  le; do not replace good clinical 
judgment about which and how much risk factors should be 
managed; no magic cut-point in deﬁ  ning classes of risk, as 
the cardiovascular risk is a continuum).
Risk charts generally identify major modiﬁ  able traditional 
risk factors (cigarette smoking, elevated blood pressure 
levels, elevated serum Total and LDL Cholesterol levels, 
low serum HDL Cholesterol levels, Diabetes Mellitus) and 
major not modiﬁ  able risk factors (age, sex, race). Other 
predisposing risk factors (abdominal obesity, physical 
inactivity, family history of premature coronary heart disease, 
psychosocial factors) or conditional risk factors (elevated 
serum triglycerides, small LDL particles, elevated serum 
homocysteine, elevated serum lipoprotein(a), C-reactive 
protein) are usually not considered. While major risk 
factors are strongly and independently related to increased 
incidence of major cardiovascular events, such as acute 
myocardial infarction, ischemic stroke or total cardiovascular 
mortality, which often represent the primary hard endpoints 
in the clinical trials, the other risk factors, even though a 
smaller quantitative contribution in determining the global 
risk proﬁ  le and not a well-deﬁ  ned role in the pathogenesis 
of cardiovascular events, have been demonstrated to be of 
relevance in the clinical management of individual patients, 
and often represent direct targets of treatment in the clinical 
practice, characterizing the so-called secondary endpoints in 
the clinical trials. In addition, it is of note that the concomitant 
presence of other not modiﬁ  able risk factors, mostly age, 
represents a condition predisposing the development and 
enhancing the deleterious effects of concomitant modiﬁ  able 
risk factors. 
A large body of risk charts and calculators to assess the 
coronary or global (coronary and cerebrovascular events) 
risk in individual patients have been proposed in the last two 
decades, since the Framingham experience (Kannel 2000). 
In this latter regard, the Framingham Score predicts either 
total coronary heart disease (CHD) (stable and unstable 
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angina pectoris, myocardial infarction and CHD death), or 
major CHD events (myocardial infarction and CHD death) 
(Kannel 2000). However, this estimation of cardiovascular 
risk implies several limitations. In fact, it derives from old 
measurements, it does not consider signiﬁ  cant differences 
among other populations, it indicates only an average value 
of risk (not individual variability), and it does not adequately 
account for severe abnormalities of risk factors (eg, severe 
hypercholesterolemia or hypertension or heavy smoking), 
leading to an underestimation of global cardiovascular 
risk. 
Recently, concerns have been raised about implementa-
tion of Framingham Risk Score in European populations 
Observational studies performed in Italy (2000), Denmark 
(2002) and Germany (2003) have clearly demonstrated 
that Framingham risk function overestimates coronary risk 
in European populations, due to a deﬁ  nition of nonfatal 
endpoints used in Framingham that is different from than 
in other cohort studies and clinical trials, and mostly to the 
objective difﬁ  culty in using local data to adjust the model 
for the use in individual European countries (Haq et al 1999; 
Menotti et al 2002; Thomsen et al 2002). In view of these 
evidence, European Society of Cardiology have carried out 
the Systematic COronary Risk Evaluation (SCORE) proj-
ect (Conroy et al 2003) for the estimation of the 10-year 
risk of fatal cardiovascular disease in Europe, as reported 
in Figure 3 (Panel A and B). The SCORE risk predictor 
system introduces several differences with respect to the 
Framingham Risk Score. First of all, it considers the total 
cardiovascular mortality rather than total cardiovascular 
events as the primary endpoint, including all atherosclerotic 
deaths (coronary artery diseases and cerebrovascular dis-
eases). Total cardiovascular risk gives a better estimate of 
individual risk, since noncoronary cardiovascular diseases 
represent a greater proportion of whole cardiovascular risk 
in European regions with low coronary artery disease. Sec-
ondly, it separates charts for lower (Belgium, France, Greece, 
Italy, Luxemburg, Spain, Switzerland, Portugal) and higher 
(United Kingdom, Sweden, Scotland, and other European 
regions) risk areas of Europe. These charts does not consider 
different algorithms for diabetic patients, in view of the facts 
that type 2 diabetes is associated per se with a 2-fold risk for 
men and 4-fold additive risk for women, determining itself 
an high-risk proﬁ  le, as also highlighted in the most recent 
guidelines (ESH/ESC 2003).
According to the SCORE, the deﬁ  nition of high total risk 
for developing a fatal cardiovascular events is represented by: 
1) patients with established cardiovascular disease; 2) asymp-
tomatic subjects who have: multiple risk factors resulting in 
a 10 year risk more than 5% now or if extrapolated to age 60 
years, or markedly raised levels of single risk factors; 3) total 
cholesterol more than 320 mg/dl, LDL cholesterol more than 
240 mg/dl, blood pressure more than 180/110 mmHg; 4) dia-
betes type 2 and diabetes type 1 with microalbuminuria. It is 
of note that total cardiovascular risk may also be higher than 
indicated in the chart in the following settings: a) in subjects 
approach the next age category; b) in asymptomatic subjects 
with preclinical evidence of atherosclerosis (eg, computer-
ized tomography or ultrasonography); c) in subjects with a 
strong family history of premature cardiovascular disease; 
d) in subjects with low HDL cholesterol levels, with raised 
triglyceride levels, with impaired glucose tolerance, and with 
raised levels of C-reactive protein, homocysteine, apolipo-
protein B or Lp(a); e) in obese and sedentary subjects. 
After risk assessment: How to 
manage global risk?
Strict application of these recommendations should never 
replace the good clinical practice and personal experience 
of physicians, which should base their decisions on the 
evidence-based medicine, rather than simple application 
of risk calculator. In fact, most hypertension-related deaths 
come from patients with only modestly raised blood pressure, 
simply because they are so much more numerous. The same 
principles apply both to cholesterol and to total risk.
Multiple drug regimens to control risk are generally 
difﬁ  cult to maintain and may be less practical and effective 
than an integrated approach to multiple risk targets by mixing 
antihypertensive drugs and other risk-lowering interventions, 
such as lipid-lowering agents and aspirin.
Within the therapeutic strategy of the management of 
hypertension, especially in patients with concomitant risk 
factors, target organ damage or co-morbidities (left ven-
tricular hypertrophy, microalbuminuria, atherosclerosis, left 
ventricular dysfunction, ischemic heart or cerebral disease 
and nephropathy), there is growing evidence supporting the 
use of newer antihypertensive drugs, such as those inhibiting 
the renin-angiotensin system (ACE Inhibitors or Angiotensin 
Receptor Blockers [ARB]) (Ruilope et al 2005). The beneﬁ  cial 
effects of antihypertensive regimens, mostly based on ARBs, 
do not seem to be exclusively linked to the documented blood 
pressure lowering effect of these compounds, and therefore 
they have been at least partially attributed to other mechanisms 
(Volpe et al 2005). In addition, clinical research from prospec-
tive trials strongly support the beneﬁ  t of using a lipid-lowering Vascular Health and Risk Management 2007:3(3) 319
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regimen in hypertensive patients, including those with other 
cardiovascular risk factors, even in patients who might not be 
candidates for such treatment, according to current guidelines 
on lipid-lowering treatment (Volpe et al 2005).
Conclusions
In conclusion, it is more appropriate to consider the global 
risk in arriving at decisions regarding clinical management 
of high-risk patients. In the modern strategies aimed at 
reducing global burden of cardiovascular disease, the over-
all risk reduction should represent the goal in the clinical 
practice, which is best achieved by establishing global risk 
proﬁ  le, identifying modiﬁ  able components of risk, and then 
starting the most effective and tolerable therapeutic strategy. 
Recent evidence strongly support a more comprehensive 
strategy aimed at reducing all the components of the global 
cardiovascular risk rather than the level of each risk factor. 
In the clinical practice, this approach has been demon-
strated to signiﬁ  cantly reduce the global burden of disease 
in hypertensive patients at high risk (NCEP 2003). In this 
regard, it is important to deﬁ  ne the global cardiovascular 
risk threshold to manage patients at high-risk, rather than to 
focus on the high level of a single risk factor, for achieving 
effective control of cardiovascular risk proﬁ  le and reduc-
ing cardiovascular morbidity and mortality in the general 
population, as well as in hypertensive population.
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